Paper19201650
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
Cohen EE and 15 others. Lancet Oncol, 2009. Cited by 210 papers, by iCite.
Cite this record
ConductScience Library. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Papers, record 19201650. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19201650
- Disease
- head and neck squamous cell carcinoma424 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
- PubMed
- Publication types
- Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| ErbB Receptors | Major topic |
| Head and Neck Neoplasms | Major topic |
| Quinazolines | Major topic |
| Vascular Endothelial Growth Factor A | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Antibodies, Monoclonal, Humanized | |
| Bevacizumab | |
| Erlotinib Hydrochloride | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Multivariate Analysis | |
| Regression Analysis | |
| Transforming Growth Factor alpha | |
| Vascular Endothelial Growth Factor Receptor-2 |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA014599 | NCI NIH HHS | United States | P30CA014599 | PubMed and NIH | NIH RePORTER |
| P30 CA14599 | NCI NIH HHS | United States | P30CA014599 | PubMed and NIH | NIH RePORTER |
| N01-CM-17102 | NCI NIH HHS | United States | PubMed | PubMed |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00055913 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 19261251 | Targeting the future in head and neck cancer. | https://conductscience.org/library/papers/19261251 |
Source PubMed
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16954439 | Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. | Endocr Relat Cancer | 2006 | https://conductscience.org/library/papers/16954439 | PubMed |
| 2 | 17704426 | Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17704426 | PubMed |
| 3 | 11157032 | Application of a new multinomial phase II stopping rule using response and early progression. | J Clin Oncol | 2001 | https://conductscience.org/library/papers/11157032 | PubMed |
| 4 | 16685275 | Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. | Br J Cancer | 2006 | https://conductscience.org/library/papers/16685275 | PubMed |
| 5 | 18784101 | Platinum-based chemotherapy plus cetuximab in head and neck cancer. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18784101 | PubMed |
| 6 | 16489018 | Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. | Cancer Res | 2006 | https://conductscience.org/library/papers/16489018 | PubMed |
| 7 | 18045071 | Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. | Curr Cancer Drug Targets | 2007 | https://conductscience.org/library/papers/18045071 | PubMed |
| 8 | 10999768 | Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. | Clin Cancer Res | 2000 | https://conductscience.org/library/papers/10999768 | PubMed |
| 9 | 12743152 | Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/12743152 | PubMed |
| 10 | 10379698 | Multinomial phase II cancer trials incorporating response and early progression. | J Biopharm Stat | 1999 | https://conductscience.org/library/papers/10379698 | PubMed |
| 11 | 17538161 | Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17538161 | PubMed |
| 12 | 11431346 | Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. | Cancer Res | 2001 | https://conductscience.org/library/papers/11431346 | PubMed |
| 13 | 16299242 | Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. | Clin Cancer Res | 2005 | https://conductscience.org/library/papers/16299242 | PubMed |
| 14 | 15701856 | Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. | Clin Cancer Res | 2005 | https://conductscience.org/library/papers/15701856 | PubMed |
| 15 | 17909199 | Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17909199 | PubMed |
| 16 | 16983506 | A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. | Invest New Drugs | 2007 | https://conductscience.org/library/papers/16983506 | PubMed |
| 17 | 17429874 | Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. | Laryngoscope | 2007 | https://conductscience.org/library/papers/17429874 | PubMed |
| 18 | 14701768 | Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. | J Clin Oncol | 2004 | https://conductscience.org/library/papers/14701768 | PubMed |
| 19 | 15908667 | Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15908667 | PubMed |
| 20 | 17876013 | Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17876013 | PubMed |
Cited by105
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 210 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40336633 | Odontogenic carcinosarcoma: a comprehensive review of clinical and therapeutic insights. | Front Oral Health | 2025 | https://conductscience.org/library/papers/40336633 | PubMed |
| 40296503 | Prospective Pilot Study of Second Primary Tumor Prevention With Erlotinib and Celecoxib in Early-Stage Squamous Cell Carcinoma of the Head and Neck: Long-Term Follow-Up. | Head Neck | 2025 | https://conductscience.org/library/papers/40296503 | PubMed |
| 39180066 | Extracellular vesicle-bound VEGF in oral squamous cell carcinoma and its role in resistance to Bevacizumab Therapy. | Cancer Cell Int | 2024 | https://conductscience.org/library/papers/39180066 | PubMed |
| 38414024 | Bioinformatic analysis and experimental validation of cuproptosis-related LncRNA as a novel biomarker for prognosis and immunotherapy of oral squamous cell carcinoma. | Hereditas | 2024 | https://conductscience.org/library/papers/38414024 | PubMed |
| 37686523 | Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer-A Step before Anakoinosis-Based Personalized Treatment. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37686523 | PubMed |
| 37341071 | Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma. | Cancer Med | 2023 | https://conductscience.org/library/papers/37341071 | PubMed |
| 36646686 | Targeted therapy for head and neck cancer: signaling pathways and clinical studies. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/36646686 | PubMed |
| 36583766 | A review of efficacy and safety of cetuximab and bevacizumab-based monoclonal antibodies in head and neck cancer. | Med Oncol | 2022 | https://conductscience.org/library/papers/36583766 | PubMed |
| 36245368 | An integrative approach toward identification and analysis of therapeutic targets involved in HPV pathogenesis with a focus on carcinomas. | Cancer Biomark | 2023 | https://conductscience.org/library/papers/36245368 | PubMed |
| 35460943 | Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials. | Transl Oncol | 2022 | https://conductscience.org/library/papers/35460943 | PubMed |
| 35158773 | NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35158773 | PubMed |
| 35047986 | Major Molecular Signaling Pathways in Oral Cancer Associated With Therapeutic Resistance. | Front Oral Health | 2020 | https://conductscience.org/library/papers/35047986 | PubMed |
| 34955687 | Using Patient-Derived Xenografts to Explore the Efficacy of Treating Head-and-Neck Squamous Cell Carcinoma With Anlotinib. | Pathol Oncol Res | 2021 | https://conductscience.org/library/papers/34955687 | PubMed |
| 34771633 | Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34771633 | PubMed |
| 34552581 | PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers. | Front Immunol | 2021 | https://conductscience.org/library/papers/34552581 | PubMed |
| 34359680 | Pre-Therapeutic VEGF Level in Plasma Is a Prognostic Bio-Marker in Head and Neck Squamous Cell Carcinoma (HNSCC). | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34359680 | PubMed |
| 34195084 | Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope? | Front Oncol | 2021 | https://conductscience.org/library/papers/34195084 | PubMed |
| 34117666 | Bleeding complications in patients with squamous cell carcinoma of the head and neck. | Head Neck | 2021 | https://conductscience.org/library/papers/34117666 | PubMed |
| 33445558 | Vascular Endothelial Growth Factor: A Translational View in Oral Non-Communicable Diseases. | Biomolecules | 2021 | https://conductscience.org/library/papers/33445558 | PubMed |
| 32280512 | An update on angiogenesis targeting in head and neck squamous cell carcinoma. | Cancers Head Neck | 2020 | https://conductscience.org/library/papers/32280512 | PubMed |
Genes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| BEVACIZUMAB | CHEMBL1201583 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1201583 | ChEMBL |
| ERLOTINIB | CHEMBL553 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL553 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19201650
GET https://conductscience.org/api/papers/v1/19201650/references?page=2